Form 4: MannKind CEO Michael Castagna Reports Stock Transactions Following RSU Vesting

Michael Castagna, CEO of MannKind Corp, reports acquisition and disposal of shares related to vesting of restricted stock units (RSUs) and tax obligations.

Summary

• Michael Castagna, the CEO of MannKind Corp, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On May 10, 2025, 298,560 shares were acquired due to the vesting of a previously reported restricted stock unit award granted on May 10, 2022.
• The vesting was contingent upon MannKind's stock price not decreasing from May 10, 2022, to May 9, 2025, and the company's total shareholder return (TSR) being at or above the 73.9th percentile of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period.
• The performance objective was achieved at 196% of target, resulting in a total share delivery of 609,560 shares.
• On May 12, 2025, 334,954 shares were disposed of at $4.56 per share to cover tax liabilities related to the vesting of the RSUs, and another 34,894 shares were disposed of at $4.56 per share for the same reason.
• On May 13, 2025, 428,000 shares were acquired pursuant to a new restricted stock unit award that vests 25% annually starting July 15, 2026.
• Additionally, on May 13, 2025, a performance-based restricted stock unit for 523,000 shares was granted, vesting on July 15, 2028, based on MannKind's TSR relative to the Russell 3000 Pharmaceutical & Biotechnology Index.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and achievement of performance targets, suggesting a moderately positive outlook.

Positives

• The vesting of the May 10, 2022 RSU award indicates that MannKind met its performance objectives, with TSR at the 73.9th percentile of the Russell 3000 Pharmaceutical & Biotechnology Index.
• The grant of new RSU awards to the CEO suggests continued confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax liabilities resulted in a decrease in the CEO's direct shareholdings.

Risks

• The vesting of the performance-based RSU granted on May 13, 2025, is contingent on MannKind's future TSR performance relative to the Russell 3000 Pharmaceutical & Biotechnology Index, which introduces uncertainty.

Future Outlook

The vesting of future RSU awards is contingent on continued performance, particularly TSR relative to the Russell 3000 Pharmaceutical & Biotechnology Index.

Industry Context

The use of TSR relative to the Russell 3000 Pharmaceutical & Biotechnology Index is a common benchmark for assessing executive performance in the pharmaceutical and biotechnology industry.

Comparison to Industry Standards

• Using TSR relative to an industry index like the Russell 3000 Pharmaceutical & Biotechnology Index is a standard practice for performance-based compensation in the biotech industry.
• Many companies, such as Amgen, Gilead Sciences, and Biogen, use similar metrics to incentivize and reward their executives.
• The percentile ranking system for TSR performance (e.g., 25th, 50th, 75th, 90th) is also a common structure for determining payout percentages of performance-based equity awards.

Stakeholder Impact

• The vesting of RSUs and subsequent share sales could have a minor impact on the company's stock price.
• The achievement of performance targets for RSU vesting is generally positive for shareholders.

Next Steps

• Future vesting of RSU awards based on continued performance.

Key Dates

Keywords

MannKind, MNKD, Michael Castagna, Form 4, RSU, Restricted Stock Unit, TSR, Total Shareholder Return, Beneficial Ownership, Vesting, Russell 3000 Pharmaceutical & Biotechnology Index